Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2019

View Archived Issues

FDA accepts IND application for ST-920 gene therapy candidate for Fabry disease

Gamida Cell presents clinical data from the NAM-NK and NiCord programs

Foresee reports topline phase III data on FP LMIS for prostate cancer

Transcriptional pathways behind the enhanced bactericidal and lysosomal properties of MPB

Ultragenyx presents positive 24-week data from first cohort of phase I/II study of DTX-401

Guangdong Zhongsheng Pharmaceutical initiates two phase I trials in patients with solid tumors

Nonmyeloablative conditioning vs. head-shielded irradiation to study brain tumor-immune interaction

Development of a novel quadruple agonist to treat nonalcoholic steatohepatitis and fibrosis

Imarikiren improves albuminuria in patients with type 2 diabetes

The European Commission grants approval for Besremi for the treatment of polycythemia vera

Abbisko Therapeutics divulges new FGFR4 inhibitors

Alphala presents new compounds for cancer

CCR5 receptor has role in stroke recovery

Bristol-Myers Squibb identifies TLR7/8/9 antagonists

Morphic Therapeutic and Janssen to collaborate on integrin therapeutics

Humira becomes the first treatment in Japan to be approved for hidradenitis suppurativa

Theravance Biopharma discloses JAK3 inhibitors

Agios Pharmaceuticals initiates phase I study of AG-636 in advanced lymphoma

Calithera initiates phase I study of the arginase inhibitor CB-280

Zeno Royalties & Milestones divulges WEE1hu inhibitors

Phase II study of OPNT-001 in bulimia nervosa does not meet primary endpoint

DEGS1 loss seen to cause hypomyelinating leukodystrophy

Durable responses seen with sacituzumab govitecan in metastatic triple-negative breast cancer

GSE-4 peptide ameliorates oxidative stress, telomere deficiency in ataxia telangiectasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...